The IL-6/sIL-6R treatment of a malignant melanoma cell line enhances susceptibility to TNF-α-induced apoptosis

Biochemical and Biophysical Research Communications

Volumn 354, Issue 4, 2007, Pages 985-991

  Wagley, Yadav ^a   Yoo, Yung Choon ^b   Seo, Han Geuk ^c   Rhee, Man Hee ^d   Kim, Tae Hyoung ^a   Kang, Keon Wook ^a   Nah, Seung Yeol ^e   Oh, Jae Wook ^a  

^a Chosun University   (South Korea)

^b Konyang University   (South Korea)

^c Gyeongsang National University School of Medicine   (South Korea)

^d Kyungpook National University   (South Korea)

^e Konkuk University   (South Korea)

Author keywords

Apoptosis; Bcl 2; Caspase 3; IL 6; sIL 6R; TNF ; TNF R55

Indexed keywords

CASPASE 3; GLYCOPROTEIN GP 130; HYBRID PROTEIN; INTERLEUKIN 6 INTERLEUKIN 6 RECEPTOR FUSION PROTEIN; NEUTRALIZING ANTIBODY; PROTEIN BCL 2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER SUSCEPTIBILITY; CELL GROWTH; CELL STIMULATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COVALENT BOND; DRUG EFFECT; DRUG INHIBITION; DRUG POTENTIATION; ENZYME ACTIVATION; FLOW CYTOMETRY; MELANOMA CELL; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINE RECEPTOR GP130; DRUG SYNERGISM; INTERLEUKIN-6; MELANOMA; MICE; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, INTERLEUKIN-6; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RECOMBINANT FUSION PROTEINS; SOLUBILITY; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 33846815255     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.01.083     Document Type: Article

References (30)

1. MacKie R.M., Bray C.A., Hole D.J., Morris A., Nicolson M., Evans A., Doherty V., and Vestey J. Incidence of and survival from malignant melanoma in Scotland: an epidemiological study. Lancet 360 (2002) 587-591
2. Komenaka I., Hoerig H., and Kaufman H.L. Immunotherapy for melanoma. Clin. Dermatol. 22 (2004) 251-265
3. Lejeune F.J., Lienard D., Matter M., and Ruegg C. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun. 6 (2006) 6
4. Agarwala S.S., and Kirkwood J.M. Interferons in melanoma. Curr. Opin. Oncol. 8 (1996) 167-174
5. Lejeune F.J., Ruegg C., and Lienard D. Clinical applications of TNF-alpha in cancer. Curr. Opin. Immunol. 10 (1998) 573-580
6. Tartaglia L.A., Ayres T.M., Wong G.H., and Goeddel D.V. A novel domain within the 55 kd TNF receptor signals cell death. Cell 74 (1993) 845-853
7. Muppidi J.R., Tschopp J., and Siegel R.M. Life and death decisions: secondary complexes and lipid rafts in TNF receptor family signal transduction. Immunity 21 (2004) 461-465
8. Novick D., Engelmann H., Wallach D., and Rubinstein M. Soluble cytokine receptors are present in normal human urine. J. Exp. Med. 170 (1989) 1409-1414
9. Frieling J.T., Sauerwein R.W., Wijdenes J., Hendriks T., and van der Linden C.J. Soluble interleukin 6 receptor in biological fluids from human origin. Cytokine 6 (1994) 376-381
10. Kyrtsonis M.C., Dedoussis G., Zervas C., Perifanis V., Baxevanis C., Stamatelou M., and Maniatis A. Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma. Br. J. Haematol. 93 (1996) 398-400
11. Kotake S., Sato K., Kim K.J., Takahashi N., Udagawa N., Nakamura I., Yamaguchi A., Kishimoto T., Suda T., and Kashiwazaki S. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J. Bone Miner. Res. 11 (1996) 88-95
12. Schwabe M., Deryugina E.I., Bosco M.C., Gusella G.L., Reinisch W., Kung H.F., and Bourdon M.A. IL-6 signals inhibition of cell adhesion in melanoma A375-C6. Anticancer Res. 16 (1996) 3363-3370
13. Itoh S., Hayashi H., Yang D., Takii T., and Onozaki K. Acquired resistance to the anti-proliferative effect of interleukin-1 and interleukin-6 is a recessive phenotype in A375 human melanoma cells. Melanoma Res. 7 (1997) 455-462
14. Oh J.W., Katz A., Harroch S., Eisenbach L., Revel M., and Chebath J. Unmasking by soluble IL-6 receptor of IL-6 effect on metastatic melanoma: growth inhibition and differentiation of B16-F10.9 tumor cells. Oncogene 15 (1997) 569-577
15. Chebath J., Fischer D., Kumar A., Oh J.W., Kolett O., Lapidot T., Fischer M., Rose-John S., Nagler A., Slavin S., and Revel M. Interleukin-6 receptor-interleukin-6 fusion proteins with enhanced interleukin-6 type pleiotropic activities. Eur. Cytokine Netw. 8 (1997) 359-365
16. Kollet O., Aviram R., Chebath J., ben-Hur H., Nagler A., Shultz L., Revel M., and Lapidot T. The soluble interleukin-6 (IL-6) receptor/IL-6 fusion protein enhances in vitro maintenance and proliferation of human CD34(+)CD38(-/low) cells capable of repopulating severe combined immunodeficiency mice. Blood 94 (1999) 923-931
17. Kang K.W., Wagley Y., Kim H.W., Pokharel Y.R., Chung Y.Y., Chang I.Y., Kim J.J., Moon J.S., Kim Y.K., Nah S.Y., Kang H.S., and Oh J.W. Novel role of IL-6/SIL-6R signaling in the expression of inducible nitric oxide synthase (iNOS) in murine B16, metastatic melanoma clone F10.9, cells. Free Radic. Biol. Med. 42 (2007) 215-227
18. Shin J.N., Seo Y.W., Kim M., Park S.Y., Lee M.J., Lee B.R., Oh J.W., Seol D.W., and Kim T.H. Cisplatin inactivation of caspases inhibits death ligand-induced cell death in vitro and fulminant liver damage in mice. J. Biol. Chem. 280 (2005) 10509-10515
19. Oh J.W., Drabik K., Kutsch O., Choi C., Tousson A., and Benveniste E.N. CXC chemokine receptor 4 expression and function in human astroglioma cells. J. Immunol. 166 (2001) 2695-2704
20. Hussein M.R., Haemel A.K., and Wood G.S. Apoptosis and melanoma: molecular mechanisms. J. Pathol. 199 (2003) 275-288
21. Zhang X., Xu Q., and Saiki I. Quercetin inhibits the invasion and mobility of murine melanoma B16-BL6 cells through inducing apoptosis via decreasing Bcl-2 expression. Clin. Exp. Metastasis 18 (2000) 415-421
22. Nakashima A., Kumakura S., Mishima S., Ishikura H., and Kobayashi S. IFN-alpha enhances TNF-alpha-induced apoptosis through down-regulation of c-Myc protein expression in HL-60 cells. J. Exp. Clin. Cancer Res. 24 (2005) 447-456
23. Baud V., and Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 11 (2001) 372-377
24. Holtmann H., Hahn T., and Wallach D. Interrelated effects of tumor necrosis factor and interleukin 1 on cell viability. Immunobiology 177 (1988) 7-22
25. Bakker T.R., Reed D., Renno T., and Jongeneel C.V. Efficient adenoviral transfer of NF-kappaB inhibitor sensitizes melanoma to tumor necrosis factor-mediated apoptosis. Int. J. Cancer 80 (1999) 320-323
26. Xie K., Wang Y., Huang S., Xu L., Bielenberg D., Salas T., McConkey D.J., Jiang W., and Fidler I.J. Nitric oxide-mediated apoptosis of K-1735 melanoma cells is associated with downregulation of Bcl-2. Oncogene 15 (1997) 771-779
27. Kovalovich K., Li W., DeAngelis R., Greenbaum L.E., Ciliberto G., and Taub R. Interleukin-6 protects against Fas-mediated death by establishing a critical level of anti-apoptotic hepatic proteins FLIP, Bcl-2, and Bcl-xL. J. Biol. Chem. 276 (2001) 26605-26613
28. Atreya R., Mudter J., Finotto S., Mullberg J., Jostock T., Wirtz S., Schutz M., Bartsch B., Holtmann M., Becker C., Strand D., Czaja J., Schlaak J.F., Lehr H.A., Autschbach F., Schurmann G., Nishimoto N., Yoshizaki K., Ito H., Kishimoto T., Galle P.R., Rose-John S., and Neurath M.F. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat. Med. 6 (2000) 583-588
29. Selzer E., Schlagbauer-Wadl H., Okamoto I., Pehamberger H., Potter R., and Jansen B. Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines. Melanoma Res. 8 (1998) 197-203
30. Micheau O., and Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114 (2003) 181-190